newsfilter
← Latest News
Business Wire·

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on